Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Depreciation and Depletion (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Depreciation and Depletion data on record, last reported at $108000.0 in Q4 2025.

  • For Q4 2025, Depreciation and Depletion fell 32.5% year-over-year to $108000.0; the TTM value through Dec 2025 reached $525000.0, down 41.92%, while the annual FY2025 figure was $525000.0, 41.92% down from the prior year.
  • Depreciation and Depletion reached $108000.0 in Q4 2025 per AMLX's latest filing, down from $120000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $315000.0 in Q1 2024 and bottomed at $10000.0 in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $152800.0, with a median of $158000.0 recorded in 2024.
  • Peak YoY movement for Depreciation and Depletion: surged 1550.0% in 2022, then tumbled 50.48% in 2025.
  • A 5-year view of Depreciation and Depletion shows it stood at $22000.0 in 2021, then surged by 727.27% to $182000.0 in 2022, then surged by 65.38% to $301000.0 in 2023, then tumbled by 46.84% to $160000.0 in 2024, then plummeted by 32.5% to $108000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $108000.0 in Q4 2025, $120000.0 in Q3 2025, and $141000.0 in Q2 2025.